Novartis

News

T-cells attacking cancer cell illustration of microscopic photos

Novartis scores first approval for PIK3CA breast cancer drug

The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.

News

Novartis gets okay for SMA gene therapy, with $2m price tag

After all the anticipation, Novartis has the FDA approval it has been seeking for Zolgensma, its gene therapy for spinal muscular atrophy, and has priced it at the low end of expectations.<

Views & Analysis

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

EU regulators accept Novartis' triple asthma combo

European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.

News

Novartis shows off pipeline - including 25 potential blockbu...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol

Novartis scores first approval for PIK3CA breast cancer drug

Novartis gets okay for SMA gene therapy, with $2m price tag

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

EU regulators accept Novartis' triple asthma combo

Novartis shows off pipeline - including 25 potential blockbu...

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks